Form 6-K BioLineRx Ltd. For: Dec 12

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Form 6-K BioLineRx Ltd. For: Dec 12

Roth Capital Lifts PT on BioLineRx (BLRX) to $10.50 Following Investor Day; BL-8040 in AML Remains Promising

December 15, 2014 8:27 AM EST

Roth Capital raises its price target on BioLineRx (Nasdaq: BLRX) from $8 up to $10.50 while maintaining a Buy rating following the company's recent investor day.

Analyst Joseph Pantginis noted the following points following BioLineRx's investor event:

We are providing further views on BioLineRx' investor event, including positive KOL views on the prospects of BL-8040 in AML. Based on the data at ASH and the expanding profile for BL-8040, we are increasing our price target to $10.50 from... More

Roth Keeps BioLineRx (BLRX) at 'Buy'; Sees BL-8040 Plan Progressing Nicely Following Recent Update

December 12, 2014 3:33 PM EST

Roth Capital affirms BioLineRx Ltd. (Nasdaq: BLRX) at Buy with a price target of $8 following the company's investor meeting this week and presented its multi-year plan for development of its CXCR4 antagonist, BL-8040.

Analyst Joseph Pantginis said, We believe BLRX is proceeding wisely with... More